Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery

Launched by ALLEGHENY SINGER RESEARCH INSTITUTE (ALSO KNOWN AS ALLEGHENY HEALTH NETWORK RESEARCH INSTITUTE) · Oct 20, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called Tamsulosin on women who experience urinary retention after pelvic reconstructive surgery. Urinary retention means having difficulty emptying the bladder, which can be uncomfortable and concerning after surgery. The trial aims to see if taking Tamsulosin can help reduce the time patients experience this issue compared to those who receive a placebo, which looks like the medication but has no active ingredients.

To participate in this study, women must be at least 18 years old, able to provide consent, and have urinary retention after their surgery, as determined by a specific test. However, those with certain health issues, such as allergies to Tamsulosin, severe heart problems, or significant kidney or liver disease, will not be eligible. Participants can expect to take either Tamsulosin or a placebo for a short period after their surgery, and the trial is currently looking for volunteers. This research could help improve care for women facing urinary retention after similar procedures.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 18 years or older
• • willing and able to provide informed consent
• • postoperative urinary retention as defined by a failed RGVT prior to hospital discharge
• • Ability to speak and read English
• • Tolerate pill ingestion
• Exclusion Criteria:
• • allergy/intolerance to Tamsulosin or sulfa drugs
• • preoperative history of urinary retention as defined by preoperative post void residual of \>150mL
• • current use of alpha antagonist medication for hypertension
• • severe dementia
• • end stage renal or liver disease
• • history of severe heart failure or major cardiovascular event in the last 6 months